RapaLink-1 ide hemihydrate Smiles: CC1CN(CCN1)C1=C(F)C=C2C(=C1OC)N(C=C(C2=O)C(O)=O)C1CC1

Smiles: CC1CN(CCN1)C1=C(F)C=C2C(=C1OC)N(C=C(C2=O)C(O)=O)C1CC1

MEISi-2 down-regulates MEIS target gene expression

Smiles: C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@@H](C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C1C=CC=C2O)N(C)C

is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity

RapaLink-1 ide hemihydrate Smiles: CC1CN(CCN1)C1=C(F)C=C2C(=C1OC)N(C=C(C2=O)C(O)=O)C1CC1RapaLink 1, the third generation bivalent mTOR inhibitor, combines Rapamycin (HY 10219) with MLN0128 (HY 13328, a second generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink 1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer derived, activating mutants of mTOR. RapaLink 1 can cross the blood brain barrier. RapaLink 1 binding to FKBP12 results in targeted and durable inhibition of